Celestial Biolabs is currently trading at Rs. 50.35, up by 2.95 points or 6.22% from its previous closing of Rs. 47.40 on the BSE.
The scrip opened at Rs. 48.35 and has touched a high and low of Rs. 50.90 and Rs. 48.15 respectively. So far 235165 shares were traded on the counter.
The BSE group 'B ' stock of face value Rs. 10 has touched a 52 week high of Rs. 50.90 on 13-Jan-2015 and a 52 week low of Rs. 15.50 on 20-Jan-2014.
Last one week high and low of the scrip stood at Rs. 50.90 and Rs. 42.20 respectively. The current market cap of the company is Rs. 84.34 crore.
The promoters holding in the company stood at 36.12% while Non-Institutions held 63.88% stake in the company.
Celestial Biolabs, a Hyderabad based Bio-pharmaceutical Company, is set to launch its latest anti-diabetic product which is expected to be a breakthrough in research and in the management of Diabetes.
Through in-house research on the anti-diabetic activities of macro algal bio-active compounds in ‘streptozotocin’ induced diabetic models has shown to be safe from acute and chronic toxicity on experimental subjects. The company is in the process of launching this natural sea based 100% vegetarian product tentatively by April 2015.
Incidentally, the GMP & ISO 9001-2008 certified, public listed company’s Research and Developmental activities have been recognized by the Department of Science and Industrial Research (DSIR), Ministry of Science and Technology, Government of India, New Delhi.
Celestial Biolabs is currently engaged in the business of manufacturing and sale of bio-pharmaceutical products.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: